Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression CAMBRIDGE, MA, USA I September 26, 2024 I Sage Therapeutics, ...

SYRACUSE, NY, USA; VANCOUVER, Canada; and BASEL, Switzerland I6, 2024 I Repair Biotechnologies, a biotechnology company developing first-in-class ...

NORTH CHICAGO, IL, USA I6, 2024 I AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-1 trial for ...

Phase 1b study will evaluate the safety and tolerability of multiple ascending doses of RCT2100 in people with cystic fibrosis – ...

CHONGQING, China I September 25, 2024 I MingMed Biotechnology, an innovative company focused on the in-house discovery and development of novel drugs, recently announced that its partially owned ...

NEW YORK, NY, USA I September 25, 2024 I Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at ...

Based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival by more than three years ...

SAN FRANCISCO, CA, USA and SUZHOU, China I September 26, 2024 I Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical ...

The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus ...

GDANSK, Poland I6, 2024 I PolTREG S.A. (Warsaw Stock Exchange: PTG), a clinical-stage biotechnology company developing cellular therapies for a ...

The collaboration will combine The Generate Platform, which integrates machine learning with high-throughput experimental validation, with Novartis expertise and capabilities in target biology, ...

Phase 1/2 clinical study will evaluate the safety and preliminary efficacy of KSQ-004EX in advanced solid tumors ...